"I am inspired by my daily interactions here with like-minded scientists driven by a passion for discovery and commitment to translating a deeper understanding of biologic processes into novel disease therapies."
I transitioned to Genentech in 2004 to extend my research focus from invertebrate genetics of developmental pathways to signal transduction biology in mammalian cancer models. Previously I led a C. elegans genetics group at Exelixis that identified novel regulators in several signaling pathways. At Genentech, a critical mass of talented scientists and extensive resources provide for a collaborative research environment that enables discovery of novel molecular mechanisms driving human diseases and translation of these discoveries into targeted therapies. I am inspired by my daily interactions here with like-minded scientists driven by a passion for discovery and commitment to translating a deeper understanding of biological processes into novel disease therapies.
Cancer Res. 2013 May 15;73(10):3132-3144.
My research group is focused on developing mechanism-based therapeutics targeting Wnt/β-catenin signaling, which is aberrantly activated at different points in the pathway in colorectal and other cancer types. We aim to better understand how β-catenin activity is regulated, and how it maintains stem-like identity and self-renewal properties in tumor cells. We utilize RNAi technology, small-molecule inhibitors, and antibodies to identify novel pathway components and investigate their mechanisms of action.